Holen Sie sich die Stockscreener-App
64.94
2.68%
-1.79
Handel nachbörslich:
65.00
0.06
+0.09%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$66.73
Offen:
$66.09
24-Stunden-Volumen:
1.31M
Relative Volume:
0.68
Marktkapitalisierung:
$8.00B
Einnahmen:
$88.04M
Nettoeinkommen (Verlust:
$-784.96M
KGV:
-9.9395
EPS:
-6.5335
Netto-Cashflow:
$-534.82M
1W Leistung:
+3.13%
1M Leistung:
+7.50%
6M Leistung:
+7.09%
1J Leistung:
+73.82%
1-Tages-Spanne:
$64.67
$66.66
1-Wochen-Bereich:
$63.80
$68.71
52-Wochen-Spanne:
$29.31
$70.98
Cytokinetics Inc Stock (CYTK) Company Profile
Firmenname
Cytokinetics Inc
Sektor
Branche
Telefon
(650) 624-3000
Adresse
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
64.94 | 8.22B | 88.04M | -784.96M | -534.82M | -6.5335 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-12-18 | Hochstufung | Goldman | Neutral → Buy |
| 2025-07-30 | Fortgesetzt | Raymond James | Mkt Perform |
| 2025-04-24 | Eingeleitet | Barclays | Overweight |
| 2025-02-07 | Eingeleitet | Citigroup | Buy |
| 2025-01-22 | Eingeleitet | Stifel | Buy |
| 2024-11-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-13 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-07 | Eingeleitet | B. Riley Securities | Buy |
| 2023-08-15 | Eingeleitet | SVB Securities | Outperform |
| 2023-02-17 | Eingeleitet | BofA Securities | Neutral |
| 2022-12-23 | Bestätigt | Needham | Buy |
| 2022-12-20 | Eingeleitet | Truist | Buy |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-01-28 | Eingeleitet | Goldman | Buy |
| 2021-12-22 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2021-02-18 | Eingeleitet | Barclays | Overweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-29 | Eingeleitet | Goldman | Neutral |
| 2020-07-10 | Eingeleitet | Raymond James | Strong Buy |
| 2020-05-05 | Eingeleitet | Mizuho | Buy |
| 2020-04-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Bestätigt | Morgan Stanley | Overweight |
| 2017-11-22 | Herabstufung | Needham | Strong Buy → Buy |
| 2017-11-21 | Bestätigt | H.C. Wainwright | Buy |
| 2017-07-31 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-03-08 | Eingeleitet | Rodman & Renshaw | Buy |
| 2017-02-06 | Hochstufung | Needham | Buy → Strong Buy |
| 2016-12-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Bestätigt | Needham | Buy |
| 2015-11-10 | Bestätigt | FBR Capital | Outperform |
| 2015-11-09 | Bestätigt | ROTH Capital | Buy |
| 2015-07-24 | Bestätigt | MLV & Co | Buy |
| 2014-12-31 | Bestätigt | ROTH Capital | Buy |
| 2014-11-04 | Hochstufung | MLV & Co | Hold → Buy |
| 2014-04-28 | Bestätigt | Needham | Buy |
Alle ansehen
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference - Bitget
Barclays Issues Positive Forecast for Cytokinetics (NASDAQ:CYTK) Stock Price - marketbeat.com
Barclays Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $95 - Moomoo
Cytokinetics, Incorporated (CYTK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cytokinetics, Incorporated (CYTK) stock price, news, quote and history - Yahoo Finance UK
Aberdeen Group plc Sells 444,771 Shares of Cytokinetics, Incorporated $CYTK - marketbeat.com
Cytokinetics MYQORZO Approval And CEO Sale Put Valuation In Focus - Yahoo! Finance Canada
Cytokinetics, Incorporated (CYTK) Stock forecasts - Yahoo Finance UK
CYTK PE Ratio & Valuation, Is CYTK Overvalued - Intellectia AI
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Connect - ACCESS Newswire
Barclays Maintains Cytokinetics(CYTK.US) With Buy Rating, Raises Target Price to $95 - Moomoo
CYTK SEC FilingsCytokinetics Inc 10-K, 10-Q, 8-K Forms - stocktitan.net
Cytokinetics (CYTK): CEO Blum sells $499k in shares - Investing.com UK
Cytokinetics (CYTK): CEO Blum sells $499k in shares By Investing.com - Investing.com Canada
Insider sale: Cytek (NASDAQ: CYTK) files to sell 45,000 RSUs - stocktitan.net
Cytokinetics (NASDAQ: CYTK) CEO sells 7,500 shares, retains large stake - stocktitan.net
CYTK Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Reach Out - ACCESS Newswire
Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CY - GuruFocus
Callos, Cytokinetics EVP, sells $236k in shares By Investing.com - Investing.com Australia
Callos, Cytokinetics EVP, sells $236k in shares - Investing.com
3,639 RSUs registered; CYTK (NASDAQ: CYTK) insider 10b5-1 sales listed - stocktitan.net
Cytokinetics (CYTK) EVP sells 3,639 shares, retains 66,004 - stocktitan.net
DAFNA Capital Management LLC's Cytokinetics Inc(CYTK) Holding History - GuruFocus
Retail Trends: Is Cytokinetics Incorporated trading at a discount2026 Summary & Low Risk Entry Point Guides - baoquankhu1.vn
Truist Financial Maintains Cytokinetics(CYTK.US) With Buy Rating - 富途牛牛
Why is Cytokinetics (CYTK) down 0.8% since last earnings report? - MSN
Cytokinetics Inc (HAM:KK3A) Stock Forecast, Price Targets and Analysts Predictions - gurufocus.com
Aug Drivers: What are the future prospects of Cytokinetics Incorporated2026 Macro Impact & Verified Entry Point Detection - baoquankhu1.vn
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates - MSN
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Cytokinetics Inc Stock Intrinsic Values | HAM:KK3A - gurufocus.com
Cytokinetics Inc (HAM:KK3A) Competitors 2026 - GuruFocus
Should you avoid Cytokinetics Incorporated stock right nowQuarterly Risk Review & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Vanguard disaggregates holdings; CYTK filings now split among subsidiaries (CYTK) - Stock Titan
Cytokinetics Inc (HAM:KK3A) Dividend - gurufocus.com
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Why Is Cytokinetics (CYTK) Down 0.8% Since Last Earnings Report? - Yahoo Finance
Cytokinetics Inc at Barclays Global Healthcare Conference Transcript - GuruFocus
Spinal Muscular Atrophy Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Genentech, Chugai Pharma, Cytokinetics, Ionis Pharma, Genzyme Corp - Barchart.com
Q3 2025 Cytokinetics Inc Earnings Call Transcript - GuruFocus
Cytokinetics (STU:KK3A) PB Ratio : (As of Mar. 26, 2026) - GuruFocus
Cytokinetics Inc (HAM:KK3A) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Aug Catalysts: What is the long term forecast for Cytokinetics Incorporated stockShort Setup & High Accuracy Trade Alerts - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
E. Ohman J or Asset Management AB Has $23.06 Million Stock Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential - The Motley Fool
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-03-22 | Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:CYTK | Press Release - Stockhouse
Cytokinetics, Incorporated $CYTK Shares Bought by Hudson Bay Capital Management LP - MarketBeat
Cytokinetics (CYTK) EVP sells 1,930 shares, retaining over 78,000 - Stock Titan
Finanzdaten der Cytokinetics Inc-Aktie (CYTK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cytokinetics Inc-Aktie (CYTK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Blum Robert I | President & CEO |
Apr 01 '26 |
Sale |
66.63 |
7,500 |
499,725 |
422,830 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):